Lavipharm S.A. (ATH:LAVI)

Market Cap	161.61M
Revenue (ttm)	55.11M
Net Income (ttm)	3.27M
Shares Out	168.69M
EPS (ttm)	0.02
PE Ratio	78.42
Forward PE	n/a
Dividend	0.02 (2.09%)
Ex-Dividend Date	Jul 17, 2025

Volume	330,821
Average Volume	187,113
Open	0.9450
Previous Close	0.9450
Day's Range	0.9440 - 0.9740
52-Week Range	0.6500 - 0.9740
Beta	0.63
RSI	79.65
Earnings Date	Mar 26, 2026

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1911
• Employees: 299
• Stock Exchange: Athens Stock Exchange
• Ticker Symbol: LAVI

Financial Performance

In 2024, Lavipharm's revenue was 52.95 million, an increase of 10.68% compared to the previous year's 47.84 million. Earnings were 8.98 million, an increase of 380.06%.